Our Contributors
Latest from BioTech Health X
- Pathology and Oncology Research Publishes Landmark Phase 3 Study: Multikine Immunotherapy Significantly Improves Survival and Quality of Life in Head and Neck Cancer Patients
- Aptose Biosciences (APTO) Stock Soars 31.50%: A Penny Stock on the Rise
- CEL-SCI Corporation: Leading the Future of Cancer Immunotherapy with Multikine®
- Ginkgo Bioworks (DNA): A Leader in Synthetic Biology Driving Innovation in 2024
- Hyperfine (HYPR)’s Swoop® Portable MRI: Transforming Emergency Neurological Care
- Quantum-Si (QSI) Stock Soars: QSI Can Be the Future of Protein Sequencing